Cabergoline-induced psychotic exacerbation in schizophrenic patients

General Hospital Psychiatry

Volumn 30, Issue 4, 2008, Pages 378-380

  Chang, Shen Chieh ^a   Chen, Chun Hsin ^a,b   Lu, Mong Liang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Cabergoline; Hyperprolactinemia; Schizophrenia

Indexed keywords

AMISULPRIDE; CABERGOLINE; FLUOXETINE; PROLACTIN; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; DELUSION; DEPRESSION; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; HUMAN; HYPERPROLACTINEMIA; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERGOLINES; FEMALE; FLUOXETINE; HUMANS; HYPERPROLACTINEMIA; PSYCHOSES, SUBSTANCE-INDUCED; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 45549107439     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2007.11.002     Document Type: Article

References (13)

1. Dickson R.A., and Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr Res 35 Suppl (1999) S75-S86
2. Tollin S.R. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23 (2000) 765-770
3. Correa N., Opler L.A., Kay S.R., and Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 7 (1987) 91-95
4. Perovich R.M., Lieberman J.A., Fleischhacker W.W., and Alvir J. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 9 (1989) 417-422
5. Nestelbaum Z., Siris S.G., Rifkin A., Klar H., and Reardon G.T. Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 143 (1986) 1170-1171
6. Rains C.P., Bryson H.M., and Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 49 (1995) 255-279
7. Cohen L.G., and Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 11 (2001) 435-440
8. Cavallaro R., Cocchi F., Angelone S.M., Lattuada E., and Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65 (2004) 187-190
9. Baeza Pertegaz I., Goikolea Alberdi J.M., and Parellada Rodon E. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms?. J Psychiatry Neurosci 27 (2002) 54
10. McKeage K., and Plosker G.L. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18 (2004) 933-956
11. Papakostas G.I., Miller K.K., Petersen T., et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 67 (2006) 952-957
12. Ahlskog J.E., Wright K.F., Muenter M.D., and Adler C.H. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 19 (1996) 202-212
13. Stiasny-Kolster K., Benes H., Peglau I., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63 (2004) 2272-2279